KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Operating Expenses: 2009-2024

Historic Operating Expenses for Neogenomics (NEO) over the last 16 years, with Dec 2024 value amounting to $382.2 million.

  • Neogenomics' Operating Expenses rose 11.85% to $107.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $429.1 million, marking a year-over-year increase of 15.12%. This contributed to the annual value of $382.2 million for FY2024, which is 8.48% up from last year.
  • Per Neogenomics' latest filing, its Operating Expenses stood at $382.2 million for FY2024, which was up 8.48% from $352.3 million recorded in FY2023.
  • In the past 5 years, Neogenomics' Operating Expenses ranged from a high of $382.2 million in FY2024 and a low of $199.9 million during FY2020.
  • For the 3-year period, Neogenomics' Operating Expenses averaged around $360.0 million, with its median value being $352.3 million (2023).
  • Data for Neogenomics' Operating Expenses shows a peak YoY surged of 52.99% (in 2021) over the last 5 years.
  • Over the past 5 years, Neogenomics' Operating Expenses (Yearly) stood at $199.9 million in 2020, then soared by 52.99% to $305.8 million in 2021, then grew by 12.98% to $345.5 million in 2022, then increased by 1.97% to $352.3 million in 2023, then rose by 8.48% to $382.2 million in 2024.